Results 251 to 260 of about 1,610,408 (351)

Predicting acute decompensated heart failure using circadian markers from heart rate time series

open access: yesESC Heart Failure, EarlyView.
Circadian metrics—amplitude, mesor, and acrophase—derived from a wrist‐worn heart rate monitor can predict acute decompensated heart failure (ADHF) up to 21 days before onset. In 65 post‐ADHF patients, an LSTM model achieved 74% sensitivity, and 73% specificity trained on 21‐day sequences. These findings support circadian rhythm analysis as a promising
Valerie A. A. van Es   +9 more
wiley   +1 more source

[2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death].

open access: yesKardiologia polska, 2015
S. Priori   +17 more
semanticscholar   +1 more source

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials

open access: yesESC Heart Failure, EarlyView.
This systematic review identified 24 clinical trials of medical device and surgical interventions for HFpEF, with 16 demonstrating at least safety and feasibility, but little evidence of long‐term benefit. Phenotype‐based responses suggest that certain interventions may benefit specific HFpEF subgroups, yet most trials suffered from heterogeneous ...
Kurdo Araz   +5 more
wiley   +1 more source

Inflammasome Signaling in Cardiac Arrhythmias: Linking Inflammation, Fibrosis, and Electrical Remodeling. [PDF]

open access: yesInt J Mol Sci
Karakasis P   +9 more
europepmc   +1 more source

Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies

open access: yesNature reviews. Immunology, 2018
P. Lazzerini   +3 more
semanticscholar   +1 more source

Four decades of heart–lung transplantation: Milestones and outcomes in advanced cardiorespiratory failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Heart–lung transplantation (HLTx) remains a life‐saving intervention for patients with end‐stage cardiopulmonary failure. We retrospectively analysed long‐term HLTx outcomes at our centre to assess survival trends and evaluate the impact of evolving immunosuppressive, surgical and perioperative strategies.
L. Lily Rosenthal   +10 more
wiley   +1 more source

Re‐PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Renal impairment frequently coexists with heart failure (HF) and is associated with increased risk of poor clinical outcomes. This highlights the urgent need for therapies targeting both cardiac and renal dysfunction. AZD3427, a long‐acting recombinant fusion protein and relaxin analogue that selectively activates the relaxin family ...
Marcin Ufnal   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy